Granules India surges on securing sole FTF ANDA status for Sodium Oxybate
Granules India is currently trading at Rs. 852.65, up by 19.50 points or 2.34% from its previous closing of Rs. 833.15 on the BSE.
The scrip opened at Rs. 840.00 and has touched a high and low of Rs. 865.00 and Rs. 834.95 respectively. So far 22380 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 865.00 on 06-Jul-2026 and a 52 week low of Rs. 433.00 on 06-Aug-2025.
Last one week high and low of the scrip stood at Rs. 865.00 and Rs. 763.35 respectively. The current market cap of the company is Rs. 21102.39 crore.
The promoters holding in the company stood at 38.02%, while Institutions and Non-Institutions held 33.61% and 28.38% respectively.
Granules India has secured Sole First-to-File (FTF) status for its Abbreviated New Drug Application (ANDA) for Sodium Oxybate Extended-Release for Oral Suspension. It is the generic equivalent of LUMRYZ extended-release oral suspension. The development further demonstrates the company’s growing capabilities in developing and advancing complex, differentiated generic products for the U.S market.
The Sole First-to-File designation further strengthens the company’s position in the complex generics segment and underscores the company’s continued focus on innovation, execution excellence, and strategic portfolio expansion in regulated markets. LUMRYZ (sodium oxybate) extended-release oral suspension is indicated in the United States for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy. LUMRYZ is a registered trademark of Alkermes plc or its affiliates.
